Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2017 Feb 20;7:42791. doi: 10.1038/srep42791

Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei

Bianca Kessler 1, Darawan Rinchai 1, Chidchamai Kewcharoenwong 1, Arnone Nithichanon 1, Rachael Biggart 2, Catherine M Hawrylowicz 3, Gregory J Bancroft 2,a, Ganjana Lertmemongkolchai 1,b
PMCID: PMC5316963  PMID: 28216665

Abstract

Melioidosis, caused by Burkholderia pseudomallei, is endemic in northeastern Thailand and Northern Australia. Severe septicemic melioidosis is associated with high levels of pro-inflammatory cytokines and is correlated with poor clinical outcomes. IL-10 is an immunoregulatory cytokine, which in other infections can control the expression of pro-inflammatory cytokines, but its role in melioidosis has not been addressed. Here, whole blood of healthy seropositive individuals (n = 75), living in N. E. Thailand was co-cultured with B. pseudomallei and production of IL-10 and IFN-γ detected and the cellular sources identified. CD3− CD14+ monocytes were the main source of IL-10. Neutralization of IL-10 increased IFN-γ, IL-6 and TNF-α production and improved bacteria killing. IFN-γ production and microbicidal activity were impaired in individuals with diabetes mellitus (DM). In contrast, IL-10 production was unimpaired in individuals with DM, resulting in an IL-10 dominant cytokine balance. Neutralization of IL-10 restored the IFN-γ response of individuals with DM to similar levels observed in healthy individuals and improved killing of B. pseudomallei in vitro. These results demonstrate that monocyte derived IL-10 acts to inhibit potentially protective cell mediated immune responses against B. pseudomallei, but may also moderate the pathological effects of excessive cytokine production during sepsis.

Burkholderia pseudomallei (B. pseudomallei) is a gram-negative bacterium that causes melioidosis. It is highly endemic in northeast Thailand and Northern Australia. However there are increasing reports in other regions such as South America, India and Malaysia1,2. In endemic areas, B. pseudomallei is isolated from soil, stagnant water and rice paddies3. Several clinical outcomes ranging from asymptomatic to localized infection, to fatal acute septicemia are associated with melioidosis4 and relapse of disease could still occur after infection and treatment3. Melioidosis is a major cause of septicemia-associated deaths in N.E. Thailand, with mortality rates of up to 40% even with current best-practice clinical management5.

Several risk factors have been associated with susceptibility to melioidosis, but diabetes mellitus (DM) is the most important, and reported in 60% of melioidosis patients6. The increased susceptibility to infection in individuals with DM has been attributed to reduced IL-12 and interferon gamma (IFN-γ) production by monocytes and natural killer (NK) cells/T cells respectively7 in response to B. pseudomallei. Polymorphonuclear leukocyte (PMNs) of Thai individuals with DM also have reduced pro-inflammatory cytokine production8, and other functions including phagocytosis, migration and apoptosis are also impaired9. PMNs also play an important role in B. pseudomallei infection in experimental models, suggesting that together, these PMNs defects are likely to contribute to the increased risk to melioidosis in individuals with DM10.

Given the spectrum of disease manifestations B. pseudomallei provokes, it is likely that the outcome of infection will be critically influenced by the balance between potentially protective pro-inflammatory responses which promote bacterial killing versus the risks of immune pathology and septic shock. Studies in mice have found that cytokines such as IFN-γ in particular but also other pro-inflammatory cytokines such as IL-12, tumor necrosis factor (TNF-α), and IL-18 are essential for resistance against B. pseudomallei since depletion of these cytokines in vivo, decreases survival and increases blood and tissue bacterial burden11,12,13,14,15. In both mice and humans, NK, CD4+ and CD8+ T cells are the cellular sources of IFN-γ in response to B. pseudomallei16,17,18,19. However, in other systems, these and other cytokines can also have a detrimental role by promoting the development of septic shock20. In the context of melioidosis, IFN-γ and its inducing cytokines, IL-18, IL-12 and IL-15 along with TNF-α and IL-6 have shown to correlate with disease severity in melioidosis patients21,22. To protect against immune-pathology, anti-inflammatory responses (such as T helper (Th) 2/regulatory T cells (Treg) and others) are crucial to control excessive pro-inflammatory cytokine cascades but to date their role in melioidosis has not been addressed.

IL-10 is a potent anti-inflammatory immunosuppressive cytokine with a broad range of effects both directly and indirectly on innate and adaptive immunity23. It is important in dampening inflammatory responses but can contribute to pathogen persistence24. Several cell types can produce IL-10 but for many infections the most important in vivo sources are monocytes, macrophages, Tregs, Th2 T cells25 and other CD4+ T cells that produce both IL-10 and IFN-γ26. In particular, macrophages produce IL-10 in a negative and positive feedback loop to dampen the uncontrolled inflammatory cytokine production during infection. IL-10 expression is tightly controlled by IFN-γ and IL-10 itself; it can limit its own expression or positively feedback to amplify its own production. In addition, IFN-γ can interfere with the IL-10 production pathway and block its production through phosphoinositide 3-kinase (PI3K)27. Increased IL-10 during infection down regulates many processes including IFN-γ production, which in turn reduces macrophage activation and disrupts the effective cellular response to clear the pathogen28. For example, in the absence of IL-10, mice infected with Mycobacterium tuberculosis have lower bacterial burdens and also improved protection when vaccinated with BCG29,30. However, the biology of IL-10 production and action in humans in the context of melioidosis is poorly understood. In acute infection with B. pseudomallei, IL-10 levels in plasma are clearly increased, and are greatest in non surviving patients22. B. pseudomallei replicates within monocytes/macrophages and induces antigen specific T cell responses, but to date the cellular source and function of IL-10 has not been investigated.

In this study we investigated IL-10 cytokine responses to B. pseudomallei in cells from individuals living in the melioidosis endemic area in northeast Thailand. Our objectives were to investigate the major cellular sources of IL-10, its potential role in the regulation of cytokine production and killing of B. pseudomallei and to determine whether altered IL-10 responses contribute to the increased risk of melioidosis in individuals with DM.

Results

B. pseudomallei induces IL-10 and IFN-γ production in individuals living in melioidosis endemic area

We have previously shown that incubation of blood from healthy individuals from the melioidosis endemic region of northeast Thailand with B. pseudomallei results in production of pro-inflammatory cytokines including TNF-α, IL-6 and in particular IFN-γ in vitro17. To now compare the balance between pro and anti-inflammatory cytokine production, whole blood of a healthy representative seropositive donor was stimulated with killed B. pseudomallei or lipopolysaccharide (LPS) (a known inducer of IL-10) and 48 hours later assayed for IL-10 and IFN-γ production by ELISA. IL-10 and IFN-γ were produced in response to killed B. pseudomallei in a dose dependent manner (data not shown), with similar kinetics, which was maximal at 48 hours of culture (Fig. 1a). When we extended this analysis to a larger donor cohort, 53 and 62 out of 75 individuals responded significantly to B. pseudomallei by producing IL-10 and IFN-γ respectively, above medium control (Fig. 1b; p < 0.001). IL-10 from 32 individuals and IFN-γ from 53 individuals also responded to LPS above medium control (Fig. 1b; p < 0.001). Other studies have shown there is an increased pro-inflammatory response to cytomegalovirus (CMV), Epstein-Barr virus (EMV) and Influenza31 with age, which may increase susceptibility to these infections. To determine if age affected the cytokine response to B. pseudomallei, we stratified the responses of the 75 donors according to age (with a range from 17 to 78 years old). We found IL-10 production in response to B. pseudomallei and LPS decreased with age (Fig. 1d; p < 0.0001). The highest IL-10 response was detected in individuals that were less than 30. Conversely IFN-γ production was not affected (Fig. 1c) by age and remained constant. The reduced IL-10 production in older individuals was not caused by changes in the number of total white blood cells, neutrophils, lymphocytes, monocytes, eosinophils and basophils (Table 1).

Figure 1. IL-10 and IFN-γ production by whole blood of healthy individuals in response to B. pseudomallei.

Figure 1

Open in a new tab

Whole blood of a healthy representative seropositive donor was incubated with killed B. pseudomallei (30:1 ratio) for 6, 12, 24 or 48 hours in vitro and supernatants assayed for IFN-γ and IL-10 (a). Whole blood of healthy seropositive donors (n = 75) was stimulated with killed B. pseudomallei (30:1 ratio) or 10 μg/ml of E. coli LPS and supernatants assayed for IFN-γ and IL-10 by ELISA after 48 hours in vitro (b). IFN-γ (c) and IL-10 (d) production in response to E. coli LPS or killed B. pseudomallei (30:1 ratio) from experiment performed in (b) were plotted according to the age of the individuals. The data in (b) are presented with the mean and the standard deviation. Statistical significance was determined using one way ANOVA and Tukey’s post test or Pearson correlation; ns, non significant, *p < 0.05, **p < 0.01 and ***p < 0.001.

Table 1. Demographic data of healthy individuals whole blood screening.

Age groups <35 35–64 >64 P value
Number of subjects 16 37 22 —
Mean age 25.5 (4.9) 49.2 (6.3) 69.8 (4.1) —
Sex (Male/Female) 6/10 6/31 4/18 Δ
WBC 7.4 (2.1) 6.1 (1.5) 6.0 (1.6) ns
Neutrophils 1.4 (4.4) 3.1 (1.0) 3.1 (0.8) *
Lymphocytes 2.3 (0.6) 2.4 (0.7) 2.1 (0.8) ns
Monocytes 0.4 (0.1) 0.3 (0.1) 0.3 (0.1) ns
Eosinophils 0.2 (0.3) 0.3 (0.2) 0.5 (0.4) *
Basophils 0.03 (0.01) 0.03 (0.02) 0.03 (0.02) ns
Open in a new tab

WBC and sub-type measures are reported in cells ×106/ml [mean (SD)].

SD = standard deviation.

Δ No effect of gender on IL-10 and IFN-γ response to B. pseudomallei and controls.

Statistical significance was determined using one-way ANOVA; ns, non significant.

*p < 0.05.

CD3−CD14+ monocytes are the major cellular source of IL-10 in response to B. pseudomallei

To identify the cellular sources of IL-10, PBMCs of seropositive healthy individuals were incubated with B. pseudomallei for 20 hours, then subsequently stained for cell surface phenotype markers (CD3 and CD14), and intracellular IL-10 and analyzed by flow cytometry. In a representative donor (Fig. 2a–c), incubation of PBMC resulted in clear induction of total IL-10+ cells and the majority was CD14+ cells within the monocyte gating area (Fig. 2a,b). In contrast, IL-10 production from CD3+ cells within the T cell gate was minimal at 20 hours and not significantly different in the presence of B. pseudomallei (Fig. 2c). The predominance of monocytes responding to B. pseudomallei for IL-10 production rather than T cells was confirmed in further 3 healthy individuals (Fig. 2d,e).

Figure 2. CD3− CD14+ monocytes are the main IL-10 producers in response to B. pseudomallei.

Figure 2

Open in a new tab

PBMCs from healthy seropositive individuals were incubated with killed B. pseudomallei for 20 hours and, intracellular IL-10 versus cell surface expression of either CD3 or CD14 detected by flow cytometry. The profile (a) of one representative donor was gated on monocytes (b) and lymphocytes (c). d and e shows the frequency of IL-10 producing CD3−CD14+ monocytes (d) or CD3+ lymphocytes (e) from multiple individuals (n = 4). The data in (d) are presented with the mean and the standard deviation. Statistical significance of killed B. pseudomallei versus medium alone was determined using paired T test; ns, non significant, *p < 0.05, **p < 0.01 and ***p < 0.001.

Neutralization of IL-10 increased IFN-γ and TNF-α production to B. pseudomallei

To assess the potential immunoregulatory effect of IL-10 on immune responses to B. pseudomallei, we first added exogenous recombinant human IL-10 to the cytokine induction assays described above. We observed dose dependent inhibition of the IFN-γ response, with complete inhibition at 1ng/ml of IL-10 added (data not shown). To examine the effect of B. pseudomallei induced IL-10 in regulating pro-inflammatory cytokine production, neutralizing anti-IL-10 was then added to PBMCs from healthy individuals in the presence of killed bacteria. Addition of anti-IL-10 monoclonal antibodies (mAb) increased IFN-γ, TNF-α and IL-6 production in a dose dependent manner (not shown) and was also observed in all B. pseudomallei to PBMCs ratios (Fig. 3a). Increased cytokine production was greatest at 48 hours but the kinetics of the effects differed according to the cytokine tested (Fig. 3b). Neutralization of IL-10 increased IFN-γ production predominantly at 48 hours, extended the total duration of the TNF-α response and increased IL-6 production at all time points. Purified monocytes also showed elevated TNF-α and IL-6 in response to B. pseudomallei at the same time points in the presence of anti-IL-10 mAb (Supplementary Fig. S1). In all 8 donors the neutralization of IL-10 also increased IFN-γ and TNF-α cytokine production (Fig. 4a,b). However IL-6 production only increased when IL-10 was neutralized in responding donors (Fig. 4c). To determine the cellular sources of the pro-inflammatory cytokines, PBMCs were stimulated for 24 hours with B. pseudomallei in the presence or absence of anti-IL-10 mAb; the surface markers of PBMCs were stained for CD3, TNF-α and IFN-γ. Flow cytometry gated on the lymphocyte population of a representative donor (Fig. 4d) showed that IL-10 neutralization increased the frequency of IFN-γ positive CD3− cells from 0.05% to 0.91% and T cells (CD3+) from 0.04% to 0.26%. The frequency of TNF-α positive cells from the CD3− monocyte population (Fig. 4e) also increased from 16.47% to 28.38%. Taken together the findings show a trend that IL-10 produced in response to B. pseudomallei may suppress the ability of monocytes, NK cells and T cells to produce pro-inflammatory cytokines.

Figure 3. Neutralization of IL-10 increases IFN-γ, TNF-α and IL-6 production in response to B. pseudomallei.

Figure 3

Open in a new tab

PBMCs of one representative donor were stimulated with killed B. pseudomallei at various ratios (0.3:1, 3:1 or 30:1) with or without the addition of anti-IL-10 mAb for 48 hours in vitro (a). Kinetics of PMBCs cytokine responses to killed B. pseudomallei (30:1 ratio) in the presence or absence of anti-IL-10 mAb for 6, 12, 24 or 48 hours in vitro (b). IFN-γ, TNF-α and IL-6 in cell supernatants were measured by ELISA. The data are presented with the mean and the standard deviation.

Figure 4. Neutralization of IL-10 increases IFN-γ and TNF-α production by CD3+ versus CD3− cells in response to B. pseudomallei.

Figure 4

Open in a new tab

PBMCs of healthy seropositive individuals (n = 8) were incubated with 10 μg/ml E. coli LPS or killed B. pseudomallei (30:1 ratio) versus medium alone and in the presence or absence of 3 μg/ml of anti-IL-10 mAb. IFN-γ (a), TNF-α (b) and IL-6 (c) production was measured by ELISA from collected supernatant after 48 hours in vitro. Each symbol represents data from an individual. The values from the same individual in the presence or absence of anti-IL-10 mAb condition are joined by a line. To identify the cellular source of cytokines, PBMCs were incubated with killed B. pseudomallei (30:1 ratio) for 20 hours and assayed by flow cytometry for intracellular IFN-γ and TNF-α versus cell surface expression of CD3. A profile of one representative donor, gated initially on lymphocytes (d) and monocytes (e) by FSC/SSC shows the frequency of IFN-γ and TNF-α producing cells respectively. Statistical significance was determined using paired T test; ns, non significant, *p < 0.05, **p < 0.01 and ***p < 0.001. IL-6 statistical significance was determined from 3 out of 6 responding donors.

Neutralization of IL-10 also enhances pro-inflammatory cytokine responses in individuals with DM

A previous study found individuals with DM in Singapore to have impaired IL-12 production that resulted in reduced IFN-γ responses to B. pseudomallei by PBMCs in vitro7. To determine whether individuals with DM in northeast Thailand also had altered cytokine responses to B. pseudomallei, the production of IFN-γ and IL-10 from healthy individuals and individuals with DM was compared (Supplementary Table S1). Whole blood was incubated with killed B. pseudomallei for 48 hours and IL-10 and IFN-γ production was determined by ELISA. In response to either B. pseudomallei or LPS, IFN-γ production was reduced in individuals with DM (Fig. 5a; p < 0.01) but IL-10 production was unimpaired in response to B. pseudomallei (Fig. 5b). The difference in IFN-γ responses between healthy individuals and individuals with DM was also observed when the individuals were also age matched, suggesting that blood glucose status and not age was the primary determinant (data not shown). The baseline of IL-6 production was high in individuals with DM when compared to healthy individuals in our PBMCs culture (Figs 4c and 6c). Neutralization of IL-10 in PBMCs from individuals with DM increased IFN-γ, TNF-α and IL-6 production (Fig. 6a–c). In particular, neutralization of IL-10 in individuals with DM restored IFN-γ responses to levels observed in healthy individuals. These observations suggest that the IL-10 is at least in part responsible for the impaired in vitro IFN-γ responses seen in these individuals who are most at risk of infection.

Figure 5. IFN-γ production in response to B. pseudomallei is reduced in individuals with DM.

Figure 5

Open in a new tab

Whole blood of healthy seropositive individuals (n = 75) and individuals with DM (n = 11) were incubated with killed B. pseudomallei (30:1 ratio), 10 μg/ml of E. coli LPS or medium alone and culture supernatants assayed for IFN-γ (a) and IL-10 (b) by ELISA after 48 hours in vitro. The data are presented with the mean and the standard deviation. Statistical significance was determined by Mann-Whitney test; ns, non significant, *p < 0.05, **p < 0.01 and ***p < 0.001.

Figure 6. Neutralization of IL-10 increases IFN-γ, TNF-α and IL-6 production in individuals with DM.

Figure 6

Open in a new tab

PBMCs (n = 5) were incubated with 10 μg/ml E. coli LPS, killed B. pseudomallei (30:1 ratio) or medium alone in the presence or absence of anti-IL-10 mAb. IFN-γ (a), TNF-α (b) and IL-6 (c) was measured by ELISA from collected supernatant after 48 hours in vitro. Each symbol represents data from an individual. The values from the same individual in the presence or absence of anti-IL-10 mAb are joined by a line. Statistical significance was determined using paired T test; ns, non significant, *p < 0.05, **p < 0.01 and ***p < 0.001.

Neutralization of IL-10 improves phagocyte-mediated killing of B. pseudomallei in both healthy individuals and individuals with DM

To ask whether IL-10 could interfere with the microbicidal activity of host cells to kill B. pseudomallei, PBMCs from healthy individuals and individuals with DM were infected with living B. pseudomallei in the presence or absence of anti-IL-10 mAb and the number of viable bacteria determined 24 hours later. Improved bacterial killing was observed in PBMCs treated with anti-IL-10 prior to infection with B. pseudomallei in both healthy individuals and individuals with DM (Fig. 7a; p < 0.05 and Fig. 7b; p < 0.001 respectively), compared to those without IL-10 neutralization. This was also observed in isolated monocytes (Supplementary Fig. S2; p < 0.01). In healthy individuals, the increased killing was associated with elevated production of IFN-γ, TNF-α and IL-6 in the presence of anti-IL-10 mAb only 6 hours after infection (Fig. 7c; p < 0.05, <0.001, <0.01 respectively). In individuals with DM (Fig. 7d; p < 0.001) neutralization of IL-10 increased TNF-α and IL-6 cytokine production but at this time point IFN-γ was not detected either in the presence or absence of IL-10 neutralization. Together, these results demonstrate that B. pseudomallei is a potent inducer of IL-10 production, which acts to regulate production of pro-inflammatory cytokines but also reduces the microbicidal activity of host cells against this pathogen in vitro.

Figure 7. Neutralization of IL-10 increases the killing of B. pseudomallei by healthy individuals and individuals with DM.

Figure 7

Open in a new tab

PBMCs from healthy individuals (n = 7) (a) and individuals with DM (n = 8) (b) were incubated with medium, live B. pseudomallei at an MOI of 1 in the presence or absence of 3 ug/ml of anti-IL-10 mAb for 6 hours. The number of live B. pseudomallei was assessed by colony forming unit assay. The cultured supernatants of healthy individuals (n = 5) (c) and individuals with DM (n = 8) (d) were assayed for IFN-γ, TNF-α and IL-6 by ELISA. Each symbol represents data from an individual. The values from the same individual in the presence or absence of anti-IL-10 mAb are joined by a line. Statistical significance was determined using paired T test; ns, non significant, *p < 0.05, **p < 0.01 and ***p < 0.001. Of note, cultured supernatants from 5 (c) out of 7 (a) healthy individuals were sufficient to be analyzed for cytokine response.

Discussion

IL-10 is a potent immunomodulatory cytokine found in the serum of individuals with acute melioidosis, but until now its cellular source, impact on host immune functions and relationship to the increased susceptibility of individuals with DM to melioidosis was not known. In this study, we have shown that incubation of intact B. pseudomallei with whole blood of healthy individuals living in the melioidosis endemic region of northeastern Thailand induces both IFN-γ and IL-10. In contrast, this balance is skewed in favor of IL-10 production in individuals with DM who are most at risk of infection. The functional consequences of this monocyte derived IL-10 response in both donor groups is to impair production of the pro-inflammatory cytokines IFN-γ, TNF-α and IL-6, and to reduce the killing of B. pseudomallei by host phagocytes.

Acute presentation with signs of pneumonia, bacteremia and septic shock are the most common and serious manifestations of human melioidosis5. Analysis of serum cytokine expression in these patients has shown increased concentrations of both pro-inflammatory cytokines, including IFN-γ, TNF-α, IL-6 and the immunoregulatory cytokine IL-1021,22, with expression of the latter two cytokines an independent predictor of mortality22. Here, we found that incubation of human peripheral blood from healthy seropositive individuals from the melioidosis endemic region of N.E. Thailand resulted in the increased expression of the same cytokines in a dose and time dependent manner in vitro. The magnitude of our response was similar to that observed with other established inducers of IL-10 secretion, and is consistent with previous reports of immune cell activation by either live or killed whole B. pseudomallei or B. pseudomallei derived LPS via a TLR-dependent process3,32,33,34. The magnitude of response in human samples may vary between individuals however we were able to show a similar trend in cytokine response in this population. However some studies in mice infected with B. pseudomallei have found no increase in IL-10 production14,35 whereas other studies using live B. pseudomallei18 or earlier time points12 were able to detect IL-10 along with other pro-inflammatory cytokines in response to infection.

Previous studies using other intracellular bacteria such as L. monocytogenes and M. tuberculosis, which share some common features in intracellular location and pathology with B. pseudomallei, found marginal zone B cells and macrophages to be the major sources of IL-10 respectively. Here, flow cytometric analysis of human PBMCs incubated with live B. pseudomallei showed CD3−CD14+ monocytes to be the main IL-10 producing cells from 6 to 20 hours of culture. In contrast, CD3+ T cells were not a substantial source of IL-10 under these conditions, despite the fact that all blood donors had evidence of adaptive immune responses to B. pseudomallei antigens by serology and the presence of antigen specific, IFN-γ secreting T cells at this time17. The magnitude in response in this low cohort of samples was able to significantly identify the main cellular source of IL-10. However additional samples may be added to confirm this finding. Nonetheless our result is consistent with our evidence to date that natural exposure to B. pseudomallei primarily induces a Th1 oriented T cell response, and suggests there is little or no expression of Th2, IL-10+ Treg or dual IFN-γ++/IL-10+ T cells in these individuals.

In other systems, IL-10 is known to inhibit many cell mediated immune responses which are involved in protection against intracellular pathogens23,36,37. IL-10 suppresses macrophage and dendritic cell (DC) functions, including intracellular pathogen killing and production of IL-12, TNF-α and IFN-γ required for effective Th1 responses38, each of which have been shown to be involved in immunity to B. pseudomallei either in animal models or in humans. Here, direct addition of rIL-10 to human PBMCs in the presence of B. pseudomallei reduced production of IFN-γ in a dose dependent manner, with complete inhibition of this response at IL-10 concentrations, which were found both in cell culture and in the serum of infected patients. Furthermore, neutralizing endogenous IL-10 in co-cultures of PBMCs with B. pseudomallei increased the production of IFN-γ, TNF-α and IL-6 in the majority of individuals tested. Thus, IL-10 produced during the innate immune response to B. pseudomallei actively regulates the pro-inflammatory cytokine response of the host. TNF-α is an important regulator of cell migration and inflammation in other bacterial infections, and mice depleted of TNF-α by neutralizing mAb in vivo have increased susceptibility to B. pseudomallei11. The direct contribution of IL-6 in melioidosis is not known but in addition to being a key component of the acute phase response, IL-6 can regulate recruitment and stimulation of neutrophils39, which are a crucial first line of defense during melioidosis9. Perhaps most importantly for control of bacterial replication, the IFN-γ response to B. pseudomallei seems to be particularly sensitive to down regulation by endogenous IL-10. IFN-γ is the primary cytokine responsible for activation of macrophages for the respiratory burst oxygen dependent killing of B. pseudomallei by macrophages40. Both NK cells and CD3+ T cells are important sources of IFN-γ in mice and humans following exposure to B. pseudomallei, and IFN-γ KO mice are exquisitely susceptibly to experimental melioidosis11,17. Here, IL-10 depletion in vitro increased IFN-γ production by both NK cells and CD3+ T cells, leading to a 10-fold increase in total IFN-γ production with more rapid kinetics allowing significant production of IFN-γ by 24 hours of culture. Furthermore, neutralizing IL-10 in mice has also shown an increased in IFN-γ response18. Importantly, neutralization of IL-10 additionally improved the killing of the bacterium by PBMCs and monocytes suggesting that these antimicrobial responses are actively down regulated by IL-10 under these conditions. Finally, IL-10 may also have other functional effects on the immune response to B. pseudomallei such as expression of type I IFNs, shown to interfere with cytokine production and increase susceptibility to other bacterial infections41 and in the induction of program death ligand 1 (PD-L1) expression42.

In melioidosis endemic regions, the incidence of acute infection is greatest in older individuals and in particular those with poorly controlled DM. In N.E. Thailand where our study was sited, melioidosis has been reported to be highest in the 55–64 age group43,44. We found IL-10 production decreased with age in response to B. pseudomallei and the TLR4 ligand, LPS. In contrast there was no association between age and production of IFN-γ in the same population. The immune responses of aging populations have mostly been studied in the context of viral infections, showing a heightened pro-inflammatory cytokine background in older individuals, which is suggested to lead to increased tissue damage31. Our study with the bacterial immune activators LPS and intact B. pseudomallei supports this possibility, although further studies on the susceptibility to melioidosis with age, independent of the confounding effect of DM in these populations, is needed.

Diabetes mellitus (DM) is the strongest predisposing risk factor for developing acute melioidosis6,45. Multiple immune defects have been described in individual with poor glycaemic control which could contribute to this susceptibly, including impaired immune function especially in neutrophils, which includes phagocytosis and the oxidative burst9. A key study in Singapore reported that type 2 diabetics had a deficiency in intracellular glutathione (GSH), which impaired production of both IL-12 and IFN-γ that led to poor control of B. pseudomallei replication7. Here we also observed reduced IFN-γ responses of PBMCs of Thai individuals with DM to both LPS and B. pseudomallei, suggesting that impairment of IFN-γ production to bacterial components is indeed a common feature of DM and may contribute to their susceptibility to a broad range of pathogens that require IFN-γ activated macrophages for their elimination46. In contrast, IL-10 responses were not impaired, resulting in an altered ratio of pro-inflammatory versus anti-inflammatory cytokine production. Importantly, neutralization of IL-10 in individuals with DM restored the reduced IFN-γ production to levels similar to the healthy individuals and increased the killing of B. pseudomallei in vitro. Although we did not detect IL-12 directly under these culture conditions, it is likely that this is mediated by changes in IL-12 since IFN-γ responses to B. pseudomallei are IL-12 dependent47, and IL-10 is well recognized to interfere with IL-12p35 and p40 production48,49. In summary, although the numbers of donors tested was not large in all assays, production of IL-10 in response to B. pseudomallei and increased pro-inflammatory cytokine production and bacterial killing were observed in the majority of individuals tested (66 out of 75 for production of IL-10, 5 out of 5 for increased IFN-γ and TNF-α secretion and 5 out of 7 donors tested for bacterial killing). Future studies using larger sample sizes and assaying the effect of IL-10 neutralization on other immune functions, such as CD8+ T cells, would further strengthen our understanding of the role of IL-10 in melioidosis.

In conclusion, we have shown that production of the immunoregulatory cytokine IL-10 is a prominent feature of the human innate immune response to B. pseudomallei, and actively inhibits both pro-inflammatory and antimicrobial responses of the host. Inhibition of the antimicrobial actions of IFN-γ, TNF-α and IL-6 are likely to increase the susceptibility of the host to infection. In contrast, IL-10-mediated control of excessive production of TNF-α and IL-6, which drive the pathological effects of the ‘cytokine storm’ found in patients with sepsis and septic shock may on the other hand be beneficial. Individuals with DM are most at risk of developing clinical melioidosis, but in contrast are less likely to die50,51. Our data showing poor IFN-γ responses but maintenance of IL-10 production in these individuals may help to explain these clinical findings. More detailed information on the effects of DM on pro-inflammatory versus immunoregulatory immune responses against B. pseudomallei should provide a better understanding of the pathogenesis of melioidosis and provide a basis for improved treatment and prevention by vaccination.

Methods

Subjects

This study utilized peripheral blood obtained from healthy individuals versus individuals with DM obtained following written informed consent, and authorized by the Khon Kaen University Ethics Committee, research number HE470506. The study was carried out in accordance with the approved guidelines and all subjects provided written informed consent. Donors attending the Khon Kaen Medical Centre, were screened for fasting blood sugar levels, blood pressure and their history of infections and hospitalization were determined. Those who had an antibody assay index to crude B. pseudomallei extract of 2 or more were considered seropositive, equivalent to an indirect hemagglutination assay (IHA) of more than 40, were included in this study52. Measurement of serum antibodies to B. pseudomallei was performed with 96 well polystyrene plates (Nunc Maxisorp) either uncoated or coated with 1 μg/ml of B. pseudomallei K96243 crude extract in 0.1 M carbonate bicarbonate buffer (pH 9.6) and incubated overnight at 4 °C. Plates were washed and 50 μl/well of 1:300 diluted human plasma were probed in duplicates. Immunoreactivity was detected by using biotinylated-rabbit anti human IgG followed by horseradish peroxidase tagged with streptavidin, after incubation for 1 hour at room temperature. The color was developed with tetramethylbenzidine substrate (BD Biosciences) and the reaction was stopped with 2 N H2SO4. Optical density (O.D) of each well was read at 450 nm and the results are represented as absorbance index of individual sample = (O.Dtest − O.Duncoated)/O.Duncoated. Healthy individuals aged between 17 and 78 years from Khon Kaen in the northeast region of Thailand used in this study were defined with fasting blood sugar of less than 126 mg/dL, normal blood pressure around 120/80 mm/Hg and had no clinical history of melioidosis. Individuals with DM, were defined as diagnosed with type 2 DM by a physician and fasting blood sugar level of more than 126 mg/dL53 at the time of blood collection. Blood samples from both groups were collected, processed and assayed in parallel in the compared experiments.

Cell culture

Whole blood (WB) was collected in heparinized tubes (BD Biosciences). The total number of lymphocytes plus monocytes was determined using an automated machine (Sysmex) and adjusted to 1.8 × 106 cells/ml with R10, which contains RPMI 1640 (Gibco), 10% heat inactivated fetal bovine serum (BioWest), 100 U/ml Penicillin/Streptomycin (Gibco), 50 μg/ml gentamycin (Sigma), and 25 mM HEPES (Gibco). Adjusted WB cells were plated in duplicates onto 96 well plates (Nalgene) and incubated in the presence of Escherichia coli (E.coli) lipopolysaccharide (LPS) 10 μg/ml (Sigma) or a 30:1 ratio of killed B. pseudomallei to PBMCs concentration. Killed B. pseudomallei was prepared from strain K96243 a clinical isolate from Thailand54; the whole bacteria were fixed with 2% paraformaldehyde for 1 hour at room temperature, washed twice with 1 × PBS (pH 7.4) and stored at −80 °C. After incubation of WB with stimuli for 48 hours at 37 °C in 5% CO2, supernatant was collected and stored at −80 °C for cytokine measurement by ELISA55.

In other experiments, human PBMCs were separated by density gradient centrifugation using Ficoll-Paque (BioWest). The PBMCs were collected and washed twice with 1 × PBS and re-suspended in R10. Cells were seeded at 5 × 106 cells/ml into a 96 well plate and incubated in the presence of the same conditions as the whole blood assay either with or without 3 μg/ml of neutralizing anti-human IL-10 (anti-IL-10) monoclonal antibodies (mAb), clone JES3-19F1 (BD Biosciences) or its isotype control, clone R35-95.

Primary human monocytes were isolated from recently separated human PBMCs by positive selection using magnetic CD14 microbeads, according to the manufacturers instructions (Miltenyi Biotec). The CD14+ cells were obtained and washed with 2 mM of EDTA in 1 × PBS and re-suspended in R10. Cells were seeded at 5 × 105 cells/ml into 96 well plates. Primary monocytes were treated with the same conditions as the PBMCs.

The concentration of IFN-γ, IL-10, IL-6 and TNF-α in supernatants from WB, PBMCs or isolated primary monocytes were measured with commercial ELISA kits (BD Biosciences) according to the manufacturers instructions.

B. pseudomallei killing assay

B. pseudomallei strain K96243, was grown to mid-log phase at 37 °C in Luria-Bertani (LB) broth and assessed by optical density at 600 nm; an absorbance index of 1 was equivalent to 109 CFU/ml of bacteria. The PBMCs or isolated primary monocytes were treated with 10 μg/ml of anti-IL-10 mAb for 15 minutes prior to infection with B. pseudomallei at multiplicity of infection (MOI) of 1 and incubated at 37 °C for 6 hours. The supernatant was collected for cytokine analysis and the infected cells were lysed by 1% Triton X-100 (Biotech). The bacterial colony count was determined by standard bacterial plating on LB agar plates after 24 hours.

Flow cytometry for detection of intracellular cytokines

PBMCs were stimulated for 2 hours before 3 μg/ml Brefeldin A (Sigma Aldrich) was added; surface and intracellular cytokine staining was performed 18 hours later. Cell surface phenotype was determined by incubating with the following mAb: anti-CD3 PerCP (clone UCHT1), anti-CD4 APC (clone OKT4), anti-CD14 FITC (clone MΦP9) (BD Biosciences). Intracellular cytokine production was detected with anti-IFN-γ FITC (clone 4SB3), anti-TNF-α PE (clone MAb11) (BioLegend) and anti-IL-10 PE (clone JES3-9D7) (BD Biosciences). Isotype matched control antibodies were used in each analysis. Data were acquired using a FACS Caliber flow cytometer and analyzed using FlowJo version 9.3.2 (Tree Star) with 50,000 cells acquired from either the monocytes or the lymphocytes population.

Data analysis

All data were analyzed for statistical significance using Prism 5 software (GraphPad) using either one way ANOVA, Tukey’s post test, Pearson correlation, paired T and Mann-Whitney test as appropriate to the experimental design and specified in the figure legends. P values of ≤0.05 were considered statistically significant.

Additional Information

How to cite this article: Kessler, B. et al. Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei. Sci. Rep. 7, 42791; doi: 10.1038/srep42791 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Supplementary Information
srep42791-s1.pdf (800.1KB, pdf)

Acknowledgments

The authors wish to acknowledge the help of nurses at Khon Kaen Medical Center and Ms Jeerawan Dhanasen in sample collection. We thank David Richards and Dr. Steve Smith for their feedback and suggestions during flow cytometry set up. This project was supported by the Centre for Research and Development of Medical and Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Thailand.

Footnotes

The authors declare no competing financial interests.

Author Contributions B.K., G.J.B. and G.L. conceived the experiments. C.M.H., G.J.B. and G.L. oversaw the study and data analysis. B.K., D.R., C.K., A.N. and R.B. performed the experiments. All authors discussed results and commented/wrote the manuscript.

References

  1. Limmathurotsakul D. et al. Increasing incidence of human melioidosis in northeast Thailand. Am. J. Trop. Med. Hyg. 82, 1113–1117 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Limmathurotsakul D. et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat. Microbiol. 1, 15008, 10.1038/nmicrobiol.2015.8 (2016). [DOI] [PubMed] [Google Scholar]
  3. Wiersinga W. J., Currie B. J. & Peacock S. J. Melioidosis. N. Engl. J. Med. 367, 1035–1044 (2012). [DOI] [PubMed] [Google Scholar]
  4. Wuthiekanun V. et al. Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. Am. J. Trop. Med. Hyg. 74, 1074–1075 (2006). [PubMed] [Google Scholar]
  5. White N. Melioidosis. The Lancet 361, 1715–1722 (2003). [DOI] [PubMed] [Google Scholar]
  6. Suputtamongkol Y. et al. Risk factors for melioidosis and bacteremic melioidosis. Clin. Infect. Dis. 29, 408–413 (1999). [DOI] [PubMed] [Google Scholar]
  7. Tan K. S. et al. Glutathione deficiency in type 2 diabetes impairs cytokine responses and control of intracellular bacteria. J. Clin. Invest. 122, 2289–2300 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kewcharoenwong C. et al. Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. Sci. Rep. 3, 3363, 10.1038/srep03363 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chanchamroen S., Kewcharoenwong C., Susaengrat W., Ato M. & Lertmemongkolchai G. Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect. Immun. 77, 456–463 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Easton A., Haque A., Chu K., Lukaszewski R. & Bancroft G. J. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J. Infect. Dis. 195, 99–107 (2007). [DOI] [PubMed] [Google Scholar]
  11. Santanirand P., Harley V. S., Dance D. A., Drasar B. S. & Bancroft G. J. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect. Immun. 67, 3593–3600 (1999). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ulett G. C., Ketheesan N. & Hirst R. G. Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 Mice during infection with virulent Burkholderia pseudomallei. Infect. Immun. 68, 2034–2042 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ulett G. C., Ketheesan N. & Hirst R. G. Proinflammatory cytokine mRNA responses in experimental Burkholderia pseudomallei infection in mice. Acta Trop. 74, 229–234 (2000). [DOI] [PubMed] [Google Scholar]
  14. Conejero L. et al. Low-dose exposure of C57BL/6 mice to Burkholderia pseudomallei mimics chronic human melioidosis. Am. J. Pathol. 179, 270–280 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hodgson K. A., Govan B. L., Walduck A. K., Ketheesan N. & Morris J. L. Impaired early cytokine responses at the site of infection in a murine model of type 2 diabetes and melioidosis comorbidity. Infect. Immun. 81, 470–477 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Haque A. et al. Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J. Infect. Dis. 193, 370–379 (2006). [DOI] [PubMed] [Google Scholar]
  17. Tippayawat P. et al. Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS Negl Trop Dis 3, e407, 10.1371/journal.pntd.0000407 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Koo G. C. & Gan Y.-H. The innate interferon gamma response of BALB/c and C57BL/6 mice to in vitro Burkholderia pseudomallei infection. BMC Immunol. 7, 19, 10.1186/1471-2172-7-19 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rowland C. A. et al. Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei. Infect. Immun. 74, 5333–5340 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Romero C. R. et al. The role of interferon-γ in the pathogenesis of acute intra-abdominal sepsis. J. Leukoc. Biol. 88, 725–735 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lauw F. N. et al. Elevated plasma concentrations of interferon (IFN)-γ and the IFN-γ-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis. J. Infect. Dis. 180, 1878–1885 (1999). [DOI] [PubMed] [Google Scholar]
  22. Simpson A. J. et al. Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J. Infect. Dis. 181, 621–625 (2000). [DOI] [PubMed] [Google Scholar]
  23. Moore K. W., de Waal Malefyt R., Coffman R. L. & O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683–765 (2001). [DOI] [PubMed] [Google Scholar]
  24. Couper K. N., Blount D. G. & Riley E. M. IL-10: the master regulator of immunity to infection. J. Immunol. 180, 5771–5777 (2008). [DOI] [PubMed] [Google Scholar]
  25. Sabat R. et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 21, 331–344 (2010). [DOI] [PubMed] [Google Scholar]
  26. Chen J. & Liu X. S. Development and function of IL-10 IFN-γ-secreting CD4+ T cells. J. Leukoc. Biol. 86, 1305–1310 (2009). [DOI] [PubMed] [Google Scholar]
  27. Saraiva M. & O’Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170–181 (2010). [DOI] [PubMed] [Google Scholar]
  28. Kane M. M. & Mosser D. M. The Role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166, 1141–1147 (2001). [DOI] [PubMed] [Google Scholar]
  29. Redford P. S. et al. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur. J. Immunol. 40, 2200–2210 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Pitt J. M. et al. Blockade of IL-10 signaling during Bacillus Calmette-Guérin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-γ and IL-17 responses and increases protection to Mycobacterium tuberculosis infection. J. Immunol. 189, 4079–4087 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Trzonkowski P. et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-an impact of immunosenescence. Vaccine 21, 3826–3836 (2003). [DOI] [PubMed] [Google Scholar]
  32. Chantratita N. et al. Survey of innate immune responses to Burkholderia pseudomallei in human blood identifies a central role for lipopolysaccharide. PLoS ONE 8, e81617, 10.1371/journal.pone.0081617 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Weehuizen T. A. F. et al. Differential toll-like receptor-signalling of Burkholderia pseudomallei lipopolysaccharide in murine and human models. PLoS ONE 10, e0145397, 10.1371/journal.pone.0145397 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Morris J. et al. Burkholderia pseudomallei triggers altered inflammatory profiles in a whole-blood model of type 2 diabetes-melioidosis comorbidity. Infect. Immun. 80, 2089–2099 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. See J.-X. et al. Experimental persistent infection of BALB/c mice with small-colony variants of Burkholderia pseudomallei leads to concurrent upregulation of PD-1 on T cells and skewed Th1 and Th17 responses. PLoS Negl Trop Dis 10, e0004503, 10.1371/journal.pntd.0004503 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Greenberger M. J. et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J. Immunol. 155, 722–729 (1995). [PubMed] [Google Scholar]
  37. Igietseme J. U. et al. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J. Immunol. 164, 4212–4219 (2000). [DOI] [PubMed] [Google Scholar]
  38. O’Garra A., Barrat F. J., Castro A. G., Vicari A. & Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 223, 114–131 (2008). [DOI] [PubMed] [Google Scholar]
  39. Dalrymple S. A. et al. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect. Immun. 63, 2262–2268 (1995). [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Breitbach K. et al. Role of inducible nitric oxide synthase and NADPH oxidase in early control of Burkholderia pseudomallei infection in mice. Infect. Immun. 74, 6300–6309 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Novikov A. et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1β production in human macrophages. J. Immunol. 187, 2540–2547 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Teijaro J. R. et al. Persistent LCMV infection is controlled by blockade of type 1 interferon signaling. Science 340, 207–211 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Saengmuang P. et al. Effect of host factors on neutrophil functions in response to Burkholderia pseudomallei in healthy Thai subjects. Jpn. J. Infect. Dis. 67, 436–440 (2014). [DOI] [PubMed] [Google Scholar]
  44. Limmathurotsakul D. et al. Increasing incidence of human melioidosis in northeast Thailand. Am. J. Trop. Med. Hyg. 82, 1113–1117 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Currie B. J., Dance D. A. B. & Cheng A. C. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans. R. Soc. Trop. Med. Hyg. 102, S1–S4 (2008). [DOI] [PubMed] [Google Scholar]
  46. Moutschen M. P., Scheen A. J. & Lefebvre P. J. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabète Métabolisme 18, 187–201 (1992). [PubMed] [Google Scholar]
  47. Lertmemongkolchai G., Cai G., Hunter C. A. & Bancroft G. J. Bystander activation of CD8+ T cells contributes to the rapid production of IFN-γ in response to bacterial pathogens. J. Immunol. 166, 1097–1105 (2001). [DOI] [PubMed] [Google Scholar]
  48. Kortylewski M. et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114–123 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Homma Y., Cao S., Shi X. & Ma X. The Th2 transcription factor c-Maf inhibits IL-12p35 gene expression in activated macrophages by targeting NF-kappaB nuclear translocation. J. Interferon Cytokine Res. 27, 799–808 (2007). [DOI] [PubMed] [Google Scholar]
  50. Koh G. C. K. W. et al. Glyburide reduces bacterial dissemination in a mouse model of melioidosis. PLoS Negl. Trop. Dis. 7, e2500; 10.1371/journal.pntd.0002500 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Koh G. C. K. W. et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin. Infect. Dis. 52, 717–725 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Cheng A. C. & Currie B. J. Melioidosis: Epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18, 383–416 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Aekplakorn W. et al. The prevalence and management of diabetes in Thai adults: the international collaborative study of cardiovascular disease in Asia. Diabetes Care 26, 2758–2763 (2003). [DOI] [PubMed] [Google Scholar]
  54. Holden M. T. G. et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl. Acad. Sci. USA 101, 14240–14245 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Suwannasaen D. et al. Human immune responses to Burkholderia pseudomallei characterized by protein microarray analysis. J. Infect. Dis. 203, 1002–1011 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep42791-s1.pdf (800.1KB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES